Biotech Co.* (Country/Symbol)

Pharma Co. (Country) (M)

Change from original agreement

Disclosed Funding

Terms/Details (Date)

Affymetrix Inc. (AFFX)

GlaxoSmithKline plc (UK)

Expanded agreement for Affymetrix GeneChip technology


The agreement enables GSK research sites to design custom GeneChip arrays on smaller format sizes that will provide them with lower-cost arrays for use in high-throughput settings (9/10)

Dendreon Corp. (DNDN)

Kirin Brewery Co. Ltd. (Japan)

Expanded agreement in which Dendreon will provide extensive clinical development and regulatory support aimed at seeking marketing approval in Asia of Provenge and Mylovenge


Kirin has all rights in Asia, but Dendreon retains all rights in North America and Europe (8/10)

GeneData AG (Switzerland)*

Bayer AG (Germany)

Extended collaboration in microbial genomics by three years


Companies will evaluate identified antibiotics to treat infectious diseases (9/17)

Genome Therapeutics Corp. (GENE)

Wyeth-Ayerst Laboratories (unit of American Home Products Corp.)

Extended genomics-based research collaboration through December 2002


The alliance, formed in 1999, is focused on the prevention and treatment of osteoporosis (7/16)

Lexicon Genetics Inc. (LEXG)

NV Organon (the Netherlands)

Renewed and expanded OmniBank Universal agreement to include access to Lexicon's research program to study the physiological in vivo function of genes


Lexicon will receive annual technology access fees and research funding from Organon (7/26)

Metabolex Inc.*

Pfizer Inc.

Realigned research partnership, shifting the focus from insulin-resistant genomics to drug targets


The restructuring includes a one-time payment to Metabolex of $6M, and three years of committed funding; Pfizer also will make an undisclosed equity investment in Metabolex (7/2)

Microcide Pharmaceuticals Inc. (MCDE)

Schering-Plough Animal Health

Amended research collaboration and license agreement increasing the level of Schering-funded research at Microcide


Collaboration focused on the discovery and development of veterinary antimicrobial drugs (7/26)

Millennium Pharmaceuticals Inc. (MLNM)

Aventis Pharmaceuticals Inc.

Addition of 11 new discovery projects to the year-old $450M collaboration


The additional discovery projects are subject to terms of the original deal, and do not add value otherwise (8/13)

Molecular Biosystems Inc. (unit of Alliance Pharmaceutical Corp.; ALLP)

Mallinckrodt Inc.

Amended agreement concerning the marketing of Optison


In the original agreement, Mallinckrodt was to pay MBI a royalty of 5% of net sales of Optison in the U.S. and Europe for as long as Mallinckrodt was marketing the product; under the amended agreement, MBI will receive an immediate cash payment, plus additional unspecified royalties for a two-year period (8/7)

MorphoSys AG (Germany; Neuer Markt:MOR)

Bayer AG (Germany)

Collaboration extended for four more years


MorphoSys will generate fully human therapeutic antibodies against up to 10 targets provided by Bayer (7/11**)

NeoGenesis Drug Discovery Inc.*

Schering-Plough Corp.

Expansion of their deal for antivirals


NeoGenesis gets a $5M equity investment from Schering-Plough, which also will provide research and development funding of about $4M per year for up to five years (8/6)

Novavax Inc. (AMEX:NOX)

King Pharmaceuticals Inc.

Expanded licensing agreement for Estrasorb


King gains exclusive rights for promotion, marketing and distribution of Estrasorb in Canada and five European countries; agreement calls for a $3M up-front licensing fee for Novavax, an additional $1M upon Estrasorb's Canadian approval and a $2M milestone fee upon the first European approval (7/2)

Onyx Pharmaceuticals Inc. (ONXX)

Pfizer Inc.

Modified agreement that returns some of the rights to ONYX-15 to Onyx


Pfizer is returning the rights to ONYX-15 only for those cancers treated by way of direct injections; Onyx will pay all costs associated with the injection efforts and will retain all profits in these applications (8/8)

QLT Inc. (Canada; QLTI)

Novartis AG (Switzerland)

Expanded alliance to co-develop photodynamic therapy with verteporfin to treat skin cancer and other dermatological conditions

C$15 (US$9.7)

Novartis will fund future development costs up to C$15M, after which the companies will share development costs and profits; QLT can receive milestones of C$2.5M for the first regulatory filing and approval (7/24)

Rigel Pharmaceuticals Inc. (RIGL)

Novartis Pharma AG (Switzerland)

Expanded deal now calling for Rigel to discover and develop small-molecule compounds that inhibit angiogenesis as a therapy for cancer


The original deal, signed in 1999, focused on five different projects aimed at identifying targets using Rigel's functional genomics technology; Rigel will receive a $4M up-front cash payment, milestones and royalty payments (7/31)


The Immune Response Corp. (IMNR)

Agouron Pharmaceuticals Inc. (acquired by Pfizer Inc.)

Termination of development rights for Remune


Agouron returned rights to Remune, an HIV product, back to Immune Response, which regains full rights in the U.S., Europe, Japan and certain other countries (7/6)


# The information in the chart does not cover agreements between biotech companies or agricultural agreements.

* Private companies are indicated with an asterisk; unless otherwise noted, stock symbols listed are on the Nasdaq market.

** Denotes the date the item ran in BioWorld International.

ND = Not disclosed, reported and/or available

AMEX = American Stock Exchange